Treatment Outcome by Randomization and Prognostic Factors
| . | LDH >700 U or Unfavorable Karyotype or Day-16 Blasts >40% . | LDH ≤700 U and Not-Unfavorable Karyotype and Day-16 Blasts ≤40% . | Other Patients . | ||||||
|---|---|---|---|---|---|---|---|---|---|
| TAD-TAD . | TAD-HAM . | P . | TAD-TAD . | TAD-HAM . | P . | TAD-TAD . | TAD-HAM . | P . | |
| No. of patients | 136 | 150 | 70 | 63 | 154 | 152 | |||
| CR | 49 (40-58) | 65 (56-73) | .004 | 81 (70-90) | 78 (65-88) | NS | 72 (64-79) | 74 (65-81) | NS |
| Event-free survival5-150 | .0125 | NS | NS | ||||||
| Prob. 5 yrs | 12 (6-18) | 17 (10-24) | 34 (22-47) | 34 (21-48) | 19 (11-26) | 29 (21-36) | |||
| Overall survival5-150 | .0118 | NS | NS | ||||||
| Prob. 5 yrs | 18 (10-25) | 25 (17-32) | 46 (32-59) | 41 (27-56) | 35 (25-44) | 36 (26-44) | |||
| RFS5-150 | NS | NS | NS | ||||||
| Prob. 5 yrs | 25 (13-37) | 26 (16-36) | 40 (25-54) | 44 (28-56) | 26 (16-35) | 38 (28-48) | |||
| . | LDH >700 U or Unfavorable Karyotype or Day-16 Blasts >40% . | LDH ≤700 U and Not-Unfavorable Karyotype and Day-16 Blasts ≤40% . | Other Patients . | ||||||
|---|---|---|---|---|---|---|---|---|---|
| TAD-TAD . | TAD-HAM . | P . | TAD-TAD . | TAD-HAM . | P . | TAD-TAD . | TAD-HAM . | P . | |
| No. of patients | 136 | 150 | 70 | 63 | 154 | 152 | |||
| CR | 49 (40-58) | 65 (56-73) | .004 | 81 (70-90) | 78 (65-88) | NS | 72 (64-79) | 74 (65-81) | NS |
| Event-free survival5-150 | .0125 | NS | NS | ||||||
| Prob. 5 yrs | 12 (6-18) | 17 (10-24) | 34 (22-47) | 34 (21-48) | 19 (11-26) | 29 (21-36) | |||
| Overall survival5-150 | .0118 | NS | NS | ||||||
| Prob. 5 yrs | 18 (10-25) | 25 (17-32) | 46 (32-59) | 41 (27-56) | 35 (25-44) | 36 (26-44) | |||
| RFS5-150 | NS | NS | NS | ||||||
| Prob. 5 yrs | 25 (13-37) | 26 (16-36) | 40 (25-54) | 44 (28-56) | 26 (16-35) | 38 (28-48) | |||
Values are percentages. In parentheses are 95% CI.
Abbreviation: NS, not significant.
From the date of the day-16 blast count.